Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 May;69(5):947–951. doi: 10.1038/bjc.1994.183

Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients.

H R Haak 1, J Hermans 1, C J van de Velde 1, E G Lentjes 1, B M Goslings 1, G J Fleuren 1, H M Krans 1
PMCID: PMC1968906  PMID: 8180029

Abstract

Mitotane is considered to be the drug of choice for patients with inoperable, recurrent and metastatic adrenocortical carcinoma, although a favourable effect of this drug on survival has never been documented. We evaluated the efficacy of mitotane treatment of 96 patients with adrenocortical carcinoma followed up in our department between 1959 and 1992. Complete tumour resection was the goal of the initial treatment. Mitotane treatment was classified according to serum trough concentrations on maintenance therapy: low (< 14 mg l-1) or high (> or = 14 mg l-1). Total tumour resection was feasible in 47 patients (49%), and subtotal resection was performed in 37 patients (39%). Patients who underwent total tumour resection survived significantly longer than those who did not (P < 0.001). Adjuvant mitotane therapy (n = 11) did not influence survival after total resection. Sixty-two patients were given mitotane treatment at some time during their illness, only 30 of whom reached high maintenance serum levels. Mitotane treatment with high serum levels had an independently favourable influence on patient survival, using univariate (P < 0.01) and multivariate analysis (P = 0.01). Mitotane treatment resulting in low serum levels was tantamount to not giving mitotane at all. We conclude that mitotane treatment in adrenocortical carcinoma is effective only when high serum levels can be achieved.

Full text

PDF
947

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Becker D., Schumacher O. P. o,p'DDD therapy in invasive adrenocortical carcinoma. Ann Intern Med. 1975 May;82(5):677–679. doi: 10.7326/0003-4819-82-5-677. [DOI] [PubMed] [Google Scholar]
  2. Bertagna C., Orth D. N. Clinical and laboratory findings and results of therapy in 58 patients with adrenocortical tumors admitted to a single medical center (1951 to 1978). Am J Med. 1981 Nov;71(5):855–875. doi: 10.1016/0002-9343(81)90384-3. [DOI] [PubMed] [Google Scholar]
  3. Eriksson B., Oberg K., Curstedt T., Hemmingsson A., Johansson H., Lindh E., Lindgren P. G., Thuomas K. A., Wilander E., Akerström G. Treatment of hormone-producing adrenocortical cancer with o,p'DDD and streptozocin. Cancer. 1987 Apr 15;59(8):1398–1403. doi: 10.1002/1097-0142(19870415)59:8<1398::aid-cncr2820590803>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  4. Haak H. R., van Seters A. P., Moolenaar A. J. Mitotane therapy of adrenocortical carcinoma. N Engl J Med. 1990 Sep 13;323(11):758–758. doi: 10.1056/NEJM199009133231115. [DOI] [PubMed] [Google Scholar]
  5. Harris D. T., Mastrangelo M. J. Theory and application of early systemic therapy. Semin Oncol. 1991 Dec;18(6):493–503. [PubMed] [Google Scholar]
  6. Hutter A. M., Jr, Kayhoe D. E. Adrenal cortical carcinoma. Clinical features of 138 patients. Am J Med. 1966 Oct;41(4):572–580. doi: 10.1016/0002-9343(66)90219-1. [DOI] [PubMed] [Google Scholar]
  7. Hutter A. M., Jr, Kayhoe D. E. Adrenal cortical carcinoma. Results of treatment with o,p'DDD in 138 patients. Am J Med. 1966 Oct;41(4):581–592. doi: 10.1016/0002-9343(66)90220-8. [DOI] [PubMed] [Google Scholar]
  8. Jarabak J., Rice K. Metastatic adrenal cortical carcinoma. Prolonged regression with mitotane therapy. JAMA. 1981 Oct 9;246(15):1706–1707. [PubMed] [Google Scholar]
  9. Johnson D. H., Greco F. A. Treatment of metastatic adrenal cortical carcinoma with cisplatin and etoposide (VP-16). Cancer. 1986 Nov 15;58(10):2198–2202. doi: 10.1002/1097-0142(19861115)58:10<2198::aid-cncr2820581006>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  10. LIPSETT M. B., HERTZ R., ROSS G. T. CLINICAL AND PATHOPHYSIOLOGIC ASPECTS OF ADRENOCORTICAL CARCINOMA. Am J Med. 1963 Sep;35:374–383. doi: 10.1016/0002-9343(63)90179-7. [DOI] [PubMed] [Google Scholar]
  11. Lubitz J. A., Freeman L., Okun R. Mitotane use in inoperable adrenal cortical carcinoma. JAMA. 1973 Mar 5;223(10):1109–1112. [PubMed] [Google Scholar]
  12. Luton J. P., Cerdas S., Billaud L., Thomas G., Guilhaume B., Bertagna X., Laudat M. H., Louvel A., Chapuis Y., Blondeau P. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med. 1990 Apr 26;322(17):1195–1201. doi: 10.1056/NEJM199004263221705. [DOI] [PubMed] [Google Scholar]
  13. MACFARLANE D. A. Cancer of the adrenal cortex; the natural history, prognosis and treatment in a study of fifty-five cases. Ann R Coll Surg Engl. 1958 Sep;23(3):155–186. [PMC free article] [PubMed] [Google Scholar]
  14. Moolenaar A. J., Niewint J. W., Oei I. T. Estimation of o,p'-DDD in plasma by gas-liquid chromatography. Clin Chim Acta. 1977 Apr 15;76(2):213–218. doi: 10.1016/0009-8981(77)90098-5. [DOI] [PubMed] [Google Scholar]
  15. Moolenaar A. J., van Slooten H., van Seters A. P., Smeenk D. Blood levels of o,p'-DDD following administration in various vehicles after a single dose and during long-term treatment. Cancer Chemother Pharmacol. 1981;7(1):51–54. doi: 10.1007/BF00258213. [DOI] [PubMed] [Google Scholar]
  16. Samaan N. A., Hickey R. C. Adrenal cortical carcinoma. Semin Oncol. 1987 Sep;14(3):292–296. [PubMed] [Google Scholar]
  17. Venkatesh S., Hickey R. C., Sellin R. V., Fernandez J. F., Samaan N. A. Adrenal cortical carcinoma. Cancer. 1989 Aug 1;64(3):765–769. doi: 10.1002/1097-0142(19890801)64:3<765::aid-cncr2820640333>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  18. van Seters A. P., Moolenaar A. J. Mitotane increases the blood levels of hormone-binding proteins. Acta Endocrinol (Copenh) 1991 May;124(5):526–533. doi: 10.1530/acta.0.1240526. [DOI] [PubMed] [Google Scholar]
  19. van Slooten H., Moolenaar A. J., van Seters A. P., Smeenk D. The treatment of adrenocortical carcinoma with o,p'-DDD: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol. 1984 Jan;20(1):47–53. doi: 10.1016/0277-5379(84)90033-6. [DOI] [PubMed] [Google Scholar]
  20. van Slooten H., van Oosterom A. T. CAP (cyclophosphamide, doxorubicin, and cisplatin) regimen in adrenal cortical carcinoma. Cancer Treat Rep. 1983 Apr;67(4):377–379. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES